Secukinumab for treating moderate to severe plaque psoriasis

Equality impact assessment - guidance development (PDF 80 KB)

Final appraisal determination information

Final appraisal determination document (PDF 220 KB)

Committee papers information

Committee papers (PDF 6.41 MB)

Psoriasis (plaque, moderate to severe) - secukinumab: equality impact assessment: scoping (PDF 14 KB)

Psoriasis (plaque, moderate to severe) - secukinumab: comments table (PDF 95 KB)

Psoriasis (plaque, moderate to severe) - secukinumab: final matrix (PDF 25 KB)

Psoriasis (plaque, moderate to severe) - secukinumab: final scope (PDF 34 KB)

Psoriasis (plaque, moderate to severe) - secukinumab: draft scope for consultation (pre-referral) - October 2013 (PDF 106 KB)

Psoriasis (plaque, moderate to severe) - secukinumab: provisional matrix (pre-referral) - October 2013 (PDF 97 KB)